毕稳稳，浙江大学杭州国际科创中心研究员、求实科创学者。2020年毕业于复旦大学基础医学院，获博士学位，博士研究生期间（2017-2019年）赴美国北卡罗莱纳大学教堂山分校莱恩伯格综合癌症中心进行联合博士培养。2020.6-2022.10在西湖大学生命科学研究院担任博士后研究员。2022.11全职加入浙江大学杭州国际科创中心任研究员。长期从事重大传染病药物（多肽、蛋白等）及疫苗等新型防治策略的研究，近年来以第一或通讯作者在Cell Reports Medicine, Cell Research, Plos Pathogens, Journal of Virology等国际学术期刊上发表多篇SCI论文，其中单篇最高影响因子46.297（发表当年）。申请专利4项，其中国际PCT专利1项，授权专利2项。
代表性论文
1.Wenwen Bi#*, Kaiming Tang#, Guilin Chen#, Yubin Xie, Nicholas F Polizzi, William F DeGrado, Shuofeng Yuan*, Bobo Dang*. An enhanced broad-spectrum peptide inhibits Omicron variants in vivo. Cell Rep Med. 2024 Feb 20;5(2):101418.
2.Wenwen Bi*, Guilin Chen, Bobo Dang*. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-spectrum Activity against SARS-CoV-2 and Its Variants. J Virol. 2022 June 23;e0068122.
3.Wenwen Bi#, Wei Xu#, Liang Cheng, Jing Xue, Qian Wang, Fei Yu, Shuai Xia, Qi Wang, Guangming Li, Chuan Qin, Lu Lu*, Lishan Su*, Shibo Jiang*. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. Plos Pathogens. 2019 Dec.5;15(12):e1008082.
4.Liang Guo #, Wenwen Bi #, Xinling Wang#, Wei Xu#, Renhong Yan#, Yuanyuan Zhang#, Kai Zhao, Yaning Li, Mingfeng Zhang, Xia Cai, Shibo Jiang, Youhua Xie, Qiang Zhou*, Lu Lu*, Bobo Dang*. Engineered trimeric ACE2 binds viral spike protein and locks it in Three-up conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 2021 Jan;31(1):98-100.
5.Qian Wang#, Wenwen Bi#, Xiaojie Zhu, Haoyang Li, Qianqian Qi, Fei Yu, Lu Lu*, Shibo Jiang*. 2015. Non-neutralizing antibodies induced by HIV-1 gp41 NHR domain gain neutralizing activity in the presence of HIV fusion inhibitor enfuvirtide: a potential therapeutic vaccine strategy. J Virol. 2015 Jul;89(13):6960-4.
6.Mengjiao Li#, Zi-Wei Ye#, Kaiming Tang#, Liang Guo#, Wenwen Bi, Yuyuan Zhang, Yan-Dong Tang, Guoguang Rong, Mohamad Sawan, Xin Yin, Ren Sun, Shuofeng Yuan*, Bobo Dang*. Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo. Cell Res. 2022 Apr 13;1-4. doi: 10.1038/s41422-022-00656-4.
7.Qian Wang#, Shan Su#, Jing Xue#, Fei Yu, Jing Pu, Wenwen Bi, Shuai Xia, Yu Meng, Cong Wang, Wenqian Yang, Wei Xu, Yun Zhu, Qinwen Zheng, Chuan Qin*, Shibo Jiang*, Lu Lu*. An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Sci Transl Med. 2020 Jun 3;12(546):eaaz2254.
专利
1.姜世勃，陆路，王茜，毕稳稳；一种艾滋病治疗性疫苗组合物及其应用,2019.10.08，中国，ZL20151 0169136. X。
2.姜世勃，陆路，毕稳稳，王茜；一种长效HIV融合抑制剂及其应用，2019.12.04，中国， ZL201610051200.9。
3.Dang Bobo, Guo Liang, Bi Wenwen, Li Mengjiao, Lu Lu, Wang Xinling, Xu Wei, Engineered ACE2 oligomers and uses thereof, PCT, PCT/CN2021/113962.
4.党波波，郭梁，毕稳稳，李梦娇；工程化ACE2寡聚物及其用途, 2021.08.23，中国,CN202180055340.2。
科研项目
1.国家自然科学基金委, 青年科学基金项目,82204264, 靶向B亚型β冠状病毒RBD和HR1高保守区的双特异蛋白广谱进入抑制剂的设计及功能研究, 2023.01-2025.12,在研,主持
